RS64746B1 - Paradigma lečenja za kombinovani tretman anti-cd19 antitelima i venetoklaksom - Google Patents
Paradigma lečenja za kombinovani tretman anti-cd19 antitelima i venetoklaksomInfo
- Publication number
- RS64746B1 RS64746B1 RS20230937A RSP20230937A RS64746B1 RS 64746 B1 RS64746 B1 RS 64746B1 RS 20230937 A RS20230937 A RS 20230937A RS P20230937 A RSP20230937 A RS P20230937A RS 64746 B1 RS64746 B1 RS 64746B1
- Authority
- RS
- Serbia
- Prior art keywords
- treatment
- antibody
- paradigm
- venetoclax combination
- venetoclax
- Prior art date
Links
- 238000011284 combination treatment Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 title 1
- 229960001183 venetoclax Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17173712 | 2017-05-31 | ||
| EP18728153.0A EP3630177B1 (en) | 2017-05-31 | 2018-05-30 | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment |
| PCT/EP2018/064229 WO2018220040A1 (en) | 2017-05-31 | 2018-05-30 | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS64746B1 true RS64746B1 (sr) | 2023-11-30 |
Family
ID=59070416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20230937A RS64746B1 (sr) | 2017-05-31 | 2018-05-30 | Paradigma lečenja za kombinovani tretman anti-cd19 antitelima i venetoklaksom |
Country Status (24)
| Country | Link |
|---|---|
| EP (2) | EP4268900A3 (sr) |
| JP (2) | JP7399713B2 (sr) |
| KR (1) | KR20200010472A (sr) |
| CN (1) | CN110678201A (sr) |
| AU (1) | AU2018276384A1 (sr) |
| BR (1) | BR112019025034A2 (sr) |
| CA (1) | CA3062400A1 (sr) |
| DK (1) | DK3630177T3 (sr) |
| ES (1) | ES2961940T3 (sr) |
| FI (1) | FI3630177T3 (sr) |
| HR (1) | HRP20231229T1 (sr) |
| HU (1) | HUE063119T2 (sr) |
| IL (2) | IL297461B1 (sr) |
| LT (1) | LT3630177T (sr) |
| MA (1) | MA48751B1 (sr) |
| MD (1) | MD3630177T2 (sr) |
| MX (1) | MX2019014330A (sr) |
| PL (1) | PL3630177T3 (sr) |
| PT (1) | PT3630177T (sr) |
| RS (1) | RS64746B1 (sr) |
| SG (1) | SG11201909715VA (sr) |
| SI (1) | SI3630177T1 (sr) |
| WO (1) | WO2018220040A1 (sr) |
| ZA (1) | ZA201907369B (sr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220241411A1 (en) * | 2020-11-30 | 2022-08-04 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
| WO2022115120A1 (en) * | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| WO2005012493A2 (en) | 2003-07-31 | 2005-02-10 | Immunomedics, Inc. | Anti-cd19 antibodies |
| EA200800094A1 (ru) | 2005-06-20 | 2008-06-30 | Медарекс, Инк. | Антитела cd19 и их использование |
| KR101397290B1 (ko) | 2005-12-30 | 2014-05-21 | 메르크 파텐트 게엠베하 | 감소한 면역원성을 가지는 항-ｃｄ19 항체 |
| SI2059536T1 (sl) | 2006-08-14 | 2014-06-30 | Xencor, Inc. | Optimirana protitelesa, ki ciljajo CD19 |
| PT2066349E (pt) | 2006-09-08 | 2012-07-02 | Medimmune Llc | Anticorpos anti-cd19 humanizados e respectiva utilização no tratamento de tumores, transplantação e doenças auto-imunes |
| EP2211904B1 (en) | 2007-10-19 | 2016-08-17 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
| KR20110122859A (ko) | 2009-02-23 | 2011-11-11 | 그렌마크 파머수티칼스 에스. 아. | Ｃｄ１９에 결합하는 인간화된 항체 및 그것의 용도 |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| ES2909722T3 (es) * | 2011-08-16 | 2022-05-10 | Morphosys Ag | Terapia de combinación con un anticuerpo anti-CD19 y una mostaza nitrogenada |
| EP4083071A3 (en) * | 2011-08-16 | 2023-02-22 | MorphoSys AG | Combination therapy with an anti-cd19 antibody and a purine analog |
| CN107921129B (zh) | 2015-08-21 | 2022-05-27 | 莫佛塞斯公司 | 组合及其用途 |
| AU2017348624A1 (en) * | 2016-10-28 | 2019-03-28 | Incyte Corporation | Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof |
-
2018
- 2018-05-30 SG SG11201909715V patent/SG11201909715VA/en unknown
- 2018-05-30 IL IL297461A patent/IL297461B1/en unknown
- 2018-05-30 MX MX2019014330A patent/MX2019014330A/es unknown
- 2018-05-30 EP EP23190328.7A patent/EP4268900A3/en active Pending
- 2018-05-30 ES ES18728153T patent/ES2961940T3/es active Active
- 2018-05-30 DK DK18728153.0T patent/DK3630177T3/da active
- 2018-05-30 IL IL270855A patent/IL270855B2/en unknown
- 2018-05-30 HU HUE18728153A patent/HUE063119T2/hu unknown
- 2018-05-30 MA MA48751A patent/MA48751B1/fr unknown
- 2018-05-30 SI SI201831004T patent/SI3630177T1/sl unknown
- 2018-05-30 KR KR1020197037961A patent/KR20200010472A/ko not_active IP Right Cessation
- 2018-05-30 RS RS20230937A patent/RS64746B1/sr unknown
- 2018-05-30 CA CA3062400A patent/CA3062400A1/en active Pending
- 2018-05-30 FI FIEP18728153.0T patent/FI3630177T3/fi active
- 2018-05-30 MD MDE20200316T patent/MD3630177T2/ro unknown
- 2018-05-30 PL PL18728153.0T patent/PL3630177T3/pl unknown
- 2018-05-30 WO PCT/EP2018/064229 patent/WO2018220040A1/en active Application Filing
- 2018-05-30 EP EP18728153.0A patent/EP3630177B1/en active Active
- 2018-05-30 JP JP2019565795A patent/JP7399713B2/ja active Active
- 2018-05-30 LT LTEPPCT/EP2018/064229T patent/LT3630177T/lt unknown
- 2018-05-30 CN CN201880035726.5A patent/CN110678201A/zh active Pending
- 2018-05-30 BR BR112019025034-4A patent/BR112019025034A2/pt unknown
- 2018-05-30 HR HRP20231229TT patent/HRP20231229T1/hr unknown
- 2018-05-30 PT PT187281530T patent/PT3630177T/pt unknown
- 2018-05-30 AU AU2018276384A patent/AU2018276384A1/en active Pending
-
2019
- 2019-11-06 ZA ZA2019/07369A patent/ZA201907369B/en unknown
-
2023
- 2023-12-06 JP JP2023205931A patent/JP2024028865A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272218A (en) | ANTI-SIRP-ALPHA ANTIBODIES AND RELATED METHODS | |
| ZA202105676B (en) | Anti-trem2 antibodies and related methods | |
| ZA202002923B (en) | Cd47 antibodies and uses thereof for treating cancer | |
| IL269593A (en) | Anti-ILT4 antibodies and antigen-binding fragments | |
| SG11202005592QA (en) | Financing Methods and Apparatuses | |
| HK1258304A1 (zh) | 優化抗cd3雙特異性抗體和其用途 | |
| DK3458478T3 (da) | Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling | |
| SG10201913206RA (en) | Antibodies comprising modified heavy constant regions | |
| MX2016015162A (es) | Anticuerpos anti - gpc3 e inmunoconjugados. | |
| PL3445785T3 (pl) | Humanizowane przeciwciała anty-clever-1 i ich zastosowanie | |
| GB202007667D0 (en) | Systems and methods for providing user-activity-based rewards and customized recommendations | |
| ZA202003858B (en) | Monoclonal antibodies and methods for using same | |
| IL272669A (en) | Combination therapy with a combination of anti-CSF1R and anti-PD-1 antibodies for pancreatic cancer | |
| IL274502A (en) | Anti-OX40 antibodies and uses thereof | |
| EP3149046A4 (en) | Humanized anti-cd19 antibody and use thereof | |
| IL270855A (en) | Therapeutic paradigm for combined anti-CD19 antibody therapy and Ventoclax | |
| IL280421A (en) | Cancer treatment by antibody | |
| IL274202A (en) | Antibodies against Glyco-Moc1 and uses thereof | |
| GB201500875D0 (en) | Antibodies for treatment and diagnosis | |
| GB201813138D0 (en) | Cancer treatment with an antibody |